EuroBiotech: More Articles of Note


> PolyProx Therapeutics, a University of Cambridge spinout, raised £3.4 million ($4.4 million) to work on drugs that engage cellular degradation machinery to stop tumor growth. Release

> 4D Pharma completed an early part of its phase 1/2 Keytruda combination trial without seeing dose-limiting toxicities. Statement 

> Freeline Therapeutics struck a multi-year agreement with Brammer Bio to secure access to gene therapy production capacity in the U.S. The capacity will support potential commercial demand for hemophilia B gene therapy FLT180a. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Baylor College of Medicine presented data on its Cell Medica-partnered GD2-CAR NKT cells. One of two patients treated with the lowest dose of the drug experienced “extensive tumor regression at four weeks.” Statement

> Amal Therapeutics teamed up with Boehringer Ingelheim to test its ATP128 in combination with anti-PD-1 antibody BI754091. Release

> Numab offloaded the Chinese rights to a trispecific antibody-based molecule targeting PD-L1, 4-1BB and human serum albumin to CStone Pharmaceuticals. Statement 

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.